BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 14628501)

  • 21. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
    Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of testosterone replacement in hypogonadal men.
    Snyder PJ; Peachey H; Berlin JA; Hannoush P; Haddad G; Dlewati A; Santanna J; Loh L; Lenrow DA; Holmes JH; Kapoor SC; Atkinson LE; Strom BL
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2670-7. PubMed ID: 10946864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testosterone treatment in elderly men.
    Srinivas-Shankar U; Sharma D
    Adv Ther; 2009 Jan; 26(1):25-39. PubMed ID: 19198768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific antigen testing in hypogonadism: implications for the safety of testosterone-replacement therapy.
    Gould DC; Feneley MR; Kirby RS
    BJU Int; 2006 Jul; 98(1):1-4. PubMed ID: 16831134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism.
    Merza Z; Blumsohn A; Mah PM; Meads DM; McKenna SP; Wylie K; Eastell R; Wu F; Ross RJ
    Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current topics in testosterone replacement of hypogonadal men.
    Nieschlag E
    Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):77-90. PubMed ID: 25617174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Testim 1% testosterone gel for the treatment of male hypogonadism.
    Bouloux P
    Clin Ther; 2005 Mar; 27(3):286-98. PubMed ID: 15878382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP; Gardette J; Rollet J; Legros JJ
    BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
    Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
    BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermal androgens: pharmacology and applicability to hypogonadal elderly men.
    Swerdloff RS; Wang C
    J Endocrinol Invest; 2005; 28(3 Suppl):112-6. PubMed ID: 16042369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testosterone treatment comes of age: new options for hypogonadal men.
    Nieschlag E
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):275-81. PubMed ID: 16918944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement.
    Ishizaka K; Suzuki M; Kageyama Y; Kihara K; Yoshida K
    Asian J Androl; 2002 Jun; 4(2):117-21. PubMed ID: 12085102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of Testim gel.
    McNicholas T; Ong T
    Expert Opin Pharmacother; 2006 Mar; 7(4):477-84. PubMed ID: 16503819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testosterone treatments: why, when, and how?
    Margo K; Winn R
    Am Fam Physician; 2006 May; 73(9):1591-8. PubMed ID: 16719252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Testosterone substitution in patients with hypogonadism].
    Martínez Portillo FJ; Cueva Martínez A; Martin Braun P; Fernández Arancibia MI; Jünemann KP; Alken P
    Arch Esp Urol; 2002 Sep; 55(7):827-38. PubMed ID: 12380312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
    Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
    Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased incidence of diagnosed depressive illness in hypogonadal older men.
    Shores MM; Sloan KL; Matsumoto AM; Moceri VM; Felker B; Kivlahan DR
    Arch Gen Psychiatry; 2004 Feb; 61(2):162-7. PubMed ID: 14757592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed?
    Greenstein A; Mabjeesh NJ; Sofer M; Kaver I; Matzkin H; Chen J
    J Urol; 2005 Feb; 173(2):530-2. PubMed ID: 15643239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testosterone replacement in men.
    Beg S; Al-Khoury L; Cunningham GR
    Curr Opin Endocrinol Diabetes Obes; 2008 Aug; 15(4):364-70. PubMed ID: 18594278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.